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OBJECTIVE — To characterize insulin action in Africans with ketosis-prone diabetes (KPD)
during remission.
RESEARCH DESIGN AND METHODS — At Saint-Louis Hospital, Paris, France, 15
African patients with KPD with an average 10.5-month insulin-free near-normoglycemic remis-
sion period (mean A1C 6.2%) were compared with 17 control subjects matched for age, sex,
BMI,andgeographicalorigin.Insulinstimulationofglucosedisposal,andinsulinsuppressionof
endogenous glucose production (EGP) and nonesteriﬁed fatty acids (NEFAs), was studied using
a 200-min two-step (10 mU   m
2 body surface   min
1 and 80 mU   m
2   min
1 insulin
infusion rates) euglycemic clamp with [6,6-
2H2]glucose as the tracer. Early-phase insulin secre-
tion was determined during an oral glucose tolerance test.
RESULTS — The total glucose disposal was reduced in patients compared with control sub-
jects(7.50.8[meanSE]vs.10.50.9mg kg
1 min
1;P0.018).EGPratewashigher
in patients than control subjects at baseline (4.0  0.3 vs. 3.0  0.1 mg   kg
1   min
1; P 
0.001) and after 200-min insulin infusion (10 mU   m
2   min
1: 1.6  0.2 vs. 0.6  0.1, P 
0.004;80mU m
2 min
1:0.30.1vs.0mg kg
1 min
1,P0.007).BasalplasmaNEFA
concentrations were also higher in patients (1,936.7  161.4 vs. 1,230.0  174.1 mol/l; P 
0.002) and remained higher after 100-min 10 mU   m
2   min
1 insulin infusion (706.6  96.5
vs. 381.6  55.9 mol/l; P  0.015).
CONCLUSIONS — The triad hepatic, adipose tissue, and skeletal muscle insulin resistance
is observed in patients with KPD during near-normoglycemic remission, suggesting that KPD is
a form of type 2 diabetes.
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I
mpairmentofinsulinsensitivityiscon-
sidered the background defect that in-
terplays with the add-on progressive
-cell dysfunction to underlie the devel-
opment of type 2 diabetes (1,2). An atyp-
ical form of diabetes, ketosis-prone
diabetes (KPD), has been described over
the past 2 decades and may represent a
signiﬁcant proportion of diabetes cases in
people of sub-Saharan African origin
(3,4). Patients with KPD present at onset
with acute hyperglycemia, usually 30
mmol/l, and ketosis or ketoacidosis as
type 1 diabetes but do not have auto-
immune markers against the islet -cell
(3,5–7). The correction of those insulin-
requiring acute-phase disorders is fol-
lowedin50%ofcasesbyaninsulin-free
near-normoglycemic remission weeks to
months later (8–10), thus resembling the
course of type 2 diabetes. The pathogen-
esis and, consequently, the classiﬁcation
of KPD are still debated. It was classiﬁed
under idiopathic type 1 diabetes or type
1B diabetes (11). However, growing evi-
dence based on clinical and metabolic
studies suggests its high phenotypical
likeness to type 2 diabetes, and “ketosis-
pronetype2diabetes”hasbeenproposed
as a provisional name and is being used
elsewhere (4,8,12). Metabolic studies
have evidenced insulin secretion deﬁ-
ciency as the major determinant of the
ketotic onset (8–10). This deﬁcit is
marked by a loss of acute-phase insulin
secretion in response to intravenous
glucose (10) or a decrease in C-peptide
response to glucagon (9,10). The sub-
sequent remission process is due to a
restoration, at least partial, of the -cell
insulin secretory capacity after achieve-
ment of good metabolic control (8,10).
Insulin action was assessed in three re-
ports, but only toward glucose metabo-
lism, and was found to be normal or
decreased while patients were in good
metabolic control (6,8,10). Moreover,
most studies on KPD have been re-
ported in African-Americans who are
more overweight than native Africans
andmaybemetabolicallydifferentfrom
them, as suggested earlier (13).
In this study, we aimed at character-
izing all aspects of insulin action in Afri-
cans with KPD when in the near-
normoglycemic state without insulin
treatmentcomparedwithcontrolsubjects
of the same geographic origin.
RESEARCH DESIGN AND
METHODS— This study was under-
taken at the Clinical Investigation Center
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France. We studied 15 subjects of sub-
Saharan African origin with KPD who
were in insulin-free remission, along with
17 healthy control subjects of the same
geographic origin, with normal glucose
tolerance. All participants were from
West and Central Africa; they were born
in Africa with no other racial antecedent
in their ancestry and had migrated to
France at adult age. KPD was deﬁned as
previously described (8). All patients had
been diagnosed, had received insulin
treatmentatdiagnosis,andwerefollowed
in the Department of Diabetes and Endo-
crinology of our hospital. Insulin-free re-
missionwasdeﬁnedasmaintenanceofan
A1C level 7.0% for at least 3 months
after the withdrawal of insulin treatment,
which was initiated at onset or relapse.
Healthy control subjects were recruited
by advertisement; they were matched to
patients for age, sex, and BMI and were
free of any family history of type 2 diabe-
tes among their ﬁrst-degree relatives. The
age at inclusion averaged 44 years in each
group. Diabetes was of short duration
(6–72 months, mean 25.2), and patients
had been in insulin-free remission for
3–45 months (mean 10.5). As antidia-
betic treatment, most patients were on
metforminalone(n8)orcombinedtoa
sulfonylurea (n  2). Two patients were
ondietalone,oneonasulfonylureaalone,
one on a glinide, and one on acarbose.
Fourpatientshadpresentedwithdiabetes
ketoacidosis (at least 2 ketonuria and
plasma bicarbonate 15 mmol/l and/or
arterial pH 7.30), whereas the others
had ketosis (at least 2 ketonuria).
Participants underwent a screening,
and those included had normal liver, car-
diovascular, pulmonary, and kidney
function assessed by medical history,
physical examination, electrocardiogra-
phy, and routine biochemical and hema-
tologicaltests,aswellasnegativehepatitis
B and C and human immunodeﬁciency
viruses’ serological tests. The A1C level
wasalsoconﬁrmedinpatientsduringthat
visit. Patients on oral antidiabetic drugs
were asked to stop them at least 5 days
before the procedures, and no healthy
control subject was taking a drug known
to affect glucose or lipid homeostasis.
Fasting blood glucose of all patients re-
mained below 8.2 mmol/l. The study was
approvedbytheethicscommitteeofParis
Saint-Louis, and each participant gave a
written informed consent to participate.
Anthropometric measurements and
dual-energy X-ray absorptiometry
In all participants, height (to the nearest
0.5 cm) was measured using a wall-stuck
stadiometer, and weight was measured to
thenearest0.1kg(SECAscale,Hamburg,
Germany). The BMI was calculated as the
weight (in kilograms) divided by the
squareoftheheight(inmeters).Thewaist
circumference (to the nearest 1 cm) was
measured at the midway between the
lower costal margin and the iliac crest,
while the person was in the upright posi-
tion, using a nonstretchable tape. Percent
fat, fat mass, and fat-free mass were mea-
sured by dual-energy X-ray absorptiom-
etry using an absorptiometer (Hologic
QDR-1000/W; Wilmington, MA). The
anthropometric characteristics and body
mass distribution were comparable be-
tween the two groups.
Metabolic assessments
Oralglucosetolerancetest. Toconﬁrm
normal glucose tolerance in control sub-
jectsandtoestimatethe-cellfunctionin
all participants, an oral glucose tolerance
test was performed on the screening visit
after a 12-h overnight fast. Blood samples
were collected before (t0) and 30 (t30)
and 120 min (t120) after a 75-g oral glu-
cose load, for determination of plasma
glucose and insulin concentrations. The
glucose tolerance status was classiﬁed ac-
cording to the current American Diabetes
Association criteria (1).
Euglycemic clamp. A two-step euglyce-
mic-hyperinsulinemic clamp was per-
formed within the week after the
screening visit, after a 12-h in-hospital
overnight fast. It consisted of a ﬁrst step
(low-dose insulin infusion) at 10 mU/m
2
bodysurfaceperminfor100mintomea-
sure the effects of insulin on plasma
nonesteriﬁed fatty acids (NEFAs). This
was followed by a primed 100-min step
(high-dose insulin infusion) at 80 mU/m
2
per min insulin infusion to evaluate the
effects of insulin on glucose disposal. The
endogenous glucose production was also
measured during the whole procedure.
Fasting (basal) blood samples were col-
lected at 70 and 60 min before the
startingoftheclamp.At60min,aprim-
ing bolus of 3 mg/kg D-[6,6-
2H2]glucose
(deuterated glucose) (96 molar percent
excess)(AssistancePublique-Ho ˆpitauxde
Paris, Paris, France) was injected, fol-
lowed by a continuous infusion at 0.05
mg   kg
1   min
1 for 260 min. Continu-
ousinsulininfusionwasthenstartedatt0,
and glucose concentration was measured
every 5 min during the whole procedure.
Blood glucose level was clamped at 5.5
mmol/l using a variable infusion of 20%
glucose, based on the negative feedback
principle(14).Arterializedbloodsamples
were drawn at baseline for the measure-
ment of basal [6,6-
2H2]glucose enrich-
ment and every 10 min during the last 20
min of each step (80th, 90th, and 100th
min and 180th, 190th, and 200th min)
for the measurement of plasma insulin,
NEFA,and[6,6-
2H2]glucoseenrichment.
Analytical techniques
All assays were run in duplicate. Plasma
glucose was measured by the hexokinase
method (Roche Diagnostics, Mannheim,
Germany). The high-performance liquid
chromatography method was used to
measure A1C.
Plasma insulin was measured using
immuno-radiometric assays (BI-
INSULIN IRMA; Cis Bio-International,
Gif-Sur-Yvette, France) with a detection
limit of 0.2 U/ml and an intra- and in-
terassay coefﬁcient of variation (CV)
9.5%.
Plasma NEFA concentrations were
determined using the colorimetric
method (Randox Laboratories, Antrim,
U.K.).
Plasma [
2H2]glucose enrichment was
measured by selected ion monitoring
electron impact gas chromatography–
mass spectrometry (5971A; Hewlett-
Packard, Palo Alto, CA) as previously
described (15). All other biochemical
tests were done using routine laboratory
methods.
Calculations
Basal concentration of each biochemical
parameter was calculated as the mean of
two values obtained from blood samples
collected 10 min apart, and the steady-
state concentrations were the average of
the three values measured 10 min apart
during the last 20 min of each step.
For endogenous glucose production
(EGP),afteranovernightfast,steady-state
conditionsforthedeuteratedglucosepre-
vailed,andthebasalEGP(bEGP)equaled
the rate of glucose appearance (Ra). It was
thereforecalculatedasthedeuteratedglu-
cose infusion rate (mg   kg
1   min
1)
dividedbytheplasmaenrichmentof[6,6-
2H2]glucose. During the two steps of the
euglycemic clamp, due to the non–
steady-state conditions, the Steele’s equa-
tion was used to estimate the Ra (16). The
residual EGP at the last 20 min of the ﬁrst
(residual EGP1 [rEGP1]) and second (re-
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clamp were therefore obtained by sub-
tracting the unlabeled glucose infusion
rate from the total Ra at each step of the
clamp. Negative values of EGP, observed
only at the high-infusion step, were con-
sidered as nil EGP. The product EGP 	
plasma insulin at basal and at the end of
each step was used as the hepatic insulin
resistance index (17).
The insulin-stimulated glucose dis-
posal rate (M) was calculated from the
glucose infusion rate during the last 20
min of the second step of the glucose
clamp after accounting for inter-
individual differences in glucose space
(14) and was expressed in milligram per
kilogram of body fat-free mass per
minute.Totalglucosedisposal(TGD)rate
was obtained by adding rEGP2 to M.
The insulinogenic index (
insulin0-30/

glucose0-30) was used to estimate the
earlyinsulinsecretionduringtheoralglu-
cose tolerance test and the product of the
TGD and the insulinogenic index as a
measure of -cell function.
The homeostasis model assessment–
insulin resistance (HOMA-IR) index was
calculated as fasting glucose (mmol/l) 	
fasting insulin (U/ml)/22.5.
At baseline and at the end of each
clamp step, we used the product mean
NEFA concentration 	 mean plasma in-
sulin as a surrogate of the adipose insulin
resistance (that is, the resistance to NEFA
suppression by insulin).
Statistical analysis
Results are represented as means  SE
and percentage, unless stated otherwise.
Statistical analysis was performed using
SPSS software version 12.0 (SPSS, Chi-
cago, IL). We used the Fisher’s exact test
to compare categorical variables and the
nonparametric Mann-Whitney U test for
quantitative variables. The level of signif-
icance was set at P  0.05.
RESULTS
Characteristics of the participants
and biochemical and metabolic
parameters
The age at inclusion and BMI were com-
parable between the two groups (Table
1).Fastingplasmaglucoselevelwas7.0
mmol/l in 87% (n  13) of patients. Dur-
ing the oral glucose tolerance test, two
patients had the proﬁle of impaired glu-
cose tolerance and others fulﬁlled the cri-
teria of diabetes. As shown in Table 1,
there was no signiﬁcant difference be-
tween patients with KPD and controls
with respect to plasma lipid parameters.
Patients had a signiﬁcantly higher fasting
plasma glucose concentration; fasting
plasma insulin levels were also higher in
patients, although the difference was not
signiﬁcant (Table 2). The insulinogenic
index was signiﬁcantly higher in the con-
trol group (Table 2). The insulinogenic
index of patients who presented initially
with ketoacidosis was not different from
that of individuals who presented with
ketosis alone (4.5  1.6 vs. 4.7  1.1;
P  0.95). During insulin infusion,
steady-state plasma insulin concentra-
tionsatthelast20minofstepone(SSPI1)
andsteptwo(SSPI2)werecomparablebe-
tween the two groups (Table 2).
Table 1—General, anthropometric, and biochemical characteristics of participants
KPD Control subjects P
n 15 17 —
Age (years) 43.9  3.0 44.0  2.1 0.9
Sex (F/M) 2/13 2/15 0.65
Age at migration to France (years) 30.3  2.0 32.2  2.1 0.54
Systolic blood pressure (mmHg) 136.9  3.9 131.6  4.8 0.23
Diastolic blood pressure (mmHg) 75.3  3.3 75.1  2.5 0.88
BMI (kg/m
2) 26.6  0.8 25.0  0.7 0.19
Waist circumference (cm) 92.4  5.8 88.1  4.3 0.74
Body fat (%) 21.1  1.2 18.5  1.9 0.1
Whole-body lean mass (kg) 58.5  2.7 58.1  2.5 0.9
Whole-body fat mass (kg) 17.2  1.7 14.0  1.6 0.18
Trunk fat mass (kg) 6.5  0.7 5.0  0.7 0.11
Total cholesterol (mmol/l) 4.9  0.3 5.5  0.3 0.12
HDL cholesterol (mmol/l) 1.4  0.1 1.6  0.1 0.13
LDL cholesterol (mmol/l) 3.0  0.2 3.5  0.3 0.18
Triglycerides (mmol/l) 1.2  0.2 1.1  0.1 0.5
Data are means  SE.
Table 2—Metabolic parameters and indexes of insulin action
KPD Control subjects P
Fasting plasma glucose (mmol/l) 6.3  0.2 4.9  0.1 0.001
Fasting plasma insulin (U/ml) 9.4  1.9 6.7  1.0 0.33
Insulinogenic index (mU/mmol) 4.6  0.9 21.3  5.4 0.001
HOMA-IR 3.1  0.6 1.1  0.2 0.005
SSPI1 (U/ml) 20.9  3.3 17.4  1.2 0.82
SSPI2 (U/ml) 189.6  20.5 181.5  14.8 0.89
TGD (mg   kg
1   min
1) 7.5  0.8 10.5  0.9 0.018
TGD 	 insulinogenic index 28.1  4.0 193.3  46.1 0.001
bEGP (mg   kg
1   min
1) 4.0  0.3 3.0  0.1 0.001
rEGP1 (mg   kg
1   min
1) 1.6  0.2 0.6  0.1 0.004
bEGP 	 FPI (mg   kg
1   min
1  
mU   l
1)
35.9  7.2 20.7  3.6 0.04
rEGP1 	 SSPI1 (mg   kg
1  
min
1   mU   l
1)
33.2  7.2 10.9  2.8 0.006
rEGP2 	 SSPI2 (mg   kg
1  
min
1   mU   l
1)
50.3  22.1 0 0.007
Fasting NEFA (mol/l) 1,936.7  161.4 1,230.0  174.1 0.002
SSNEFA1 (mol/l) 706.6  96.5 381.6  55.9 0.015
SSNEFA2 (mol/l) 187.8  27.7 116.1  11.2 0.05
Fasting IRNEFA (10
3   mol  
mU   l
2)
17.7  3.2 8.0  1.7 0.009
IRNEFA1 (10
3   mol   mU   l
2) 17.4  4.6 6.9  1.4 0.05
IRNEFA2 (10
3   mol   mU   l
2) 40.2  9.2 21.2  2.6 0.06
DataaremeansSE.SSNEFA,steady-statenonesteriﬁedfattyacid;IRNEFA,insulinresistanceindextoNEFA
disappearance(1and 2denotethelast20minoftheﬁrstandsecondstepsoftheglucoseclamp,respectively).
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Mean TGD rate was reduced by 30% in
KPD patients (P  0.018) (Table 2). This
difference remained signiﬁcant after ad-
justment for BMI (P  0.034). The
HOMA-IRwasaccordinglyhigherinKPD
patients. The product of TGD and insuli-
nogenicindexwasalsomarkedlyreduced
in KPD patients compared with control
subjects (Table 2).
Endogenous glucose production
The EGP was signiﬁcantly higher in pa-
tientsatbaseline(bEGP)andattheendof
theﬁrststep(rEGP1)oftheglucoseclamp
(Table 2). During the last step of the
clamp, rEGP2 was 0 in control subjects,
whereas it was still positive in four pa-
tients,andthedifferencebetweenthetwo
groups was signiﬁcant (P  0.007). The
EGP as a function of the plasma insulin
level (dose-response curve) is displayed
in Fig. 1A. The hepatic insulin resistance
index was 33% higher in patients at basal
(bEGP 	 fasting plasma insulin). During
bothlow-dose(rEGP1	SSPI1)andhigh-
dose (rEGP2 	 SSPI2) insulin infusions,
this index remained higher in patients
(Table 2).
NEFA suppression
Basal NEFA concentration was 57%
higher in patients compared with control
subjects (Table 2), even after adjustment
for BMI (P  0.024). It remained signiﬁ-
cantly elevated at the end of the low-dose
insulin infusion step (SSNEFA1) and at
theborderlinesigniﬁcancelevelattheend
ofthehigh-doseinsulininfusionstep(SS-
NEFA2) of the euglycemic clamp (Table
2). By contrast, the relative decline from
baseline was similar between the two
groups,whateverthestep(inpatientsand
control subjects, respectively: ﬁrst step
61.5  5.5 vs. 64.9  4.2%, P  0.7;
second step 89.5  1.8 vs. 88.2  1.6%,
P  0.5). Figure 1B presents the plasma
NEFA concentration as a function of
plasma insulin levels. Insulin resistance
index to NEFA disappearance (IRNEFA)
was doubled in patients compared with
controlsatbasal(fastingIRNEFA)anddur-
ingtheclamp(IRNEFA1andIRNEFA2),with
the difference being statistically signiﬁ-
cant at basal but at borderline signiﬁ-
cance at the ﬁrst and second steps
(Table 2).
CONCLUSIONS — Because ketosis
is the hallmark of KPD, the role of insulin
secretionhasbeenwidelystudiedatonset
and in the long-term course of the disease
(6,8–10). In two among these studies, in-
sulin sensitivity toward glucose metabo-
lism was evaluated using either the
euglycemic clamp (6) or the minimal
model (10). Compared with control sub-
jects’ values, it was reported to be similar
(10) or reduced (6) in patients with or
without insulin treatment after they re-
covered from the acute ketotic episode.
We also previously used the intravenous
insulin tolerance test to evaluate insulin
sensitivity in a larger cohort of KPD pa-
tients (8). We showed that, although
markedly impaired during the ketotic
phase,insulinsensitivityimprovedsignif-
icantly after 6 months of follow-up and
almost reached nondiabetic values in pa-
tients who became insulin independent
but not in patients who still required in-
sulin for metabolic control.
In the present study, to assess various
aspects of insulin action in patients with
KPD in near-normoglycemic remission, we
used a two-step euglycemic-hyperinsuline-
mic clamp to compare them with matched
control subjects with normal glucose toler-
ance. This allowed us to provide a direct
and complete characterization of insulin
sensitivity in a phenotype of diabetes that
still requires thorough insight for appropri-
ate classiﬁcation and treatment. The ﬁrst
ﬁnding of our study is that despite insulin-
free near-normoglycemic remission in sub-
Saharan African adults with KPD, insulin-
mediated glucose disposal is markedly
reduced. This was previously suggested by
Banerji et al. (6) in patients with KPD in
good metabolic control, either insulin
treated or not.
Another important ﬁnding is that de-
spiteinsulin-freenear-normoglycemicre-
mission, in the postabsorptive state,
patientswithKPDdisplayahigherendog-
enous glucose production rate, which
mostly corresponds to hepatic glucose
production (18). This is related to an in-
creased hepatic insulin resistance as evi-
dencedbythehigherbasalhepaticinsulin
resistance index (bEGP 	 fasting plasma
insulin). During both low- and high-dose
insulin infusions, this index remained
higher in patients, indicating that for a
Figure 1—Endogenous glucose production rate (A) and plasma NEFA concentrations (B)a t
baseline and during insulin infusion in KPD patients (F) and control subjects (Œ). Values repre-
sent means  SE. *P  0.05, †P  0.01 vs. control subjects.
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sionofEGPwaslessmarkedinthemcom-
pared with control subjects.
Our last important ﬁnding is that at
fasting and during the low-dose insulin
infusion, plasma NEFA concentrations
were higher in patients than in control
subjects. This was substantiated by the
higher basal adipose insulin resistance in-
dex, demonstrating that KPD patients in
near-normoglycemic remission display
adipose insulin resistance. Of note, in-
creased circulating NEFAs may in turn
worsen insulin resistance and the insulin
secretion defect. The lack of difference in
NEFAresponsetoinsulininfusionmaybe
related to the good metabolic control of
patients or to the small number of sub-
jects studied. Absolute basal NEFA con-
centrations seem quite high in our
subjects. This may be because we did not
use a lipolysis inhibitor during blood
sample collection, although higher NEFA
levels have been previously reported in
black populations (19).
Reduced muscle glucose uptake and
decreased liver and adipose insulin sensi-
tivity have also been reported in Cauca-
sians with type 2 diabetes by Groop et al.
(20) and are usually considered as char-
acteristic features of type 2 diabetes
(21,22). However, in these reports, dia-
betic patients were hyperglycemic, with
mean fasting plasma glucose at 10.5
mmol/l (22) or A1C level averaging 9.6%
(20). In our study, patients were in near-
normoglycemia with mean A1C level at
6.2%. Although all antidiabetic medica-
tions, if any, were discontinued many
days before the investigation, fasting
plasma glucose averaged 6.3 mmol/l and
was below the diabetic-deﬁning cutoff of
7 mmol/l in 87% of patients. Thus, this is
the ﬁrst investigation of diabetic patients
in a metabolic state close to normoglyce-
mia without insulin treatment. The mul-
tiorgan insulin resistance observed in
near-normoglycemia suggests that these
defects are primary rather than secondary
to the diabetic state. We also show that
theimpairmentofinsulinsensitivityisas-
sociated with a decreased early-phase in-
sulin secretion resulting in a drastically
reduced index of -cell function (TGD 	
insulinogenic index). Indeed, it is now
recognized that type 2 diabetes develops
when insulin secretion is unable to com-
pensate for insulin resistance (23,24).
The fact that patients with KPD dis-
play metabolic abnormalities that charac-
terizetype2diabetesdoesnotexplainthe
ketotic onset or relapses that deﬁne KPD.
A genetic defect or an environmental fac-
tormakingthe-cellsmoresusceptibleto
gluco-and/orlipotoxicitymaybeapoten-
tial factor. To date, no prominent genetic
factor has been identiﬁed. We recently
proposed that an endemic asymptomatic
viral infection may be the ketotic precip-
itating factor in such patients from sub-
Saharan Africa. Among possible
candidates, we focused on human herpes-
virus-8 (HHV-8). We found a high associ-
ation between KPD and HHV-8 infection
and evidenced that this virus was able to
infect human -cells in vitro (25).
We acknowledge that the small
number of subjects may have mini-
mized the role of BMI and/or percent
body fat on the insulin sensitivity de-
fects. Indeed, these anthropometric pa-
rameters were slightly higher in
patients, although not signiﬁcantly.
However, adjustment for BMI or per-
cent body fat did not change the signif-
icance of our results. Also, it should be
noted that despite the near-normogly-
cemic state, the higher fasting plasma
glucose in patients might have by itself
worsened the insulinogenic index (26).
In conclusion, in the context of near-
normoglycemicremission,weobservein-
sulin resistance at the level of muscle,
adipose tissue, and liver. As suggested in
reports on the recovery of -cell function
after the acute phase of KPD (8,10), these
ﬁndings strongly indicate that KPD is a
subtype of type 2 diabetes in which an
uncommon factor triggers the ketotic on-
set or relapses.
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